Dacoplice (Dacomitinib) Tablet

Description

Description

This page contains brief details about the drug dacomitinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Dacomitinib is an anticancer agent belonging to the category of kinase inhibitors which was approved for its medical use in 2018.

Mechanism of Action of Dacomitinib

Dacomitinib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified under protein tyrosine kinase inhibitors. It has potent activity against EGFR genes (genes that are prominent in non-small cell lung cancer and some types of breast cancer undergoing mutation). On acting against EGFR genes, Dacomitinib interrupts cell signaling and arrests the growth of cancer cells.

Uses of Dacomitinib

Dacomitinib Tablet has been approved to treat non-small cell lung cancer that has spread to other organs.

Dacomitinib Dosage available

Dacomitinib is available as a film-coated tablet in the doses 15mg, 30mg and 45mg. The recommended dose is 45mg once a day with or without food. It is advisable to swallow the whole tablet and take them at the same time each day. Your healthcare provider may alter the dose depending on how well your body tolerates it.